PRESS RELEASE published on 07/21/2025 at 20:52, 1 year 1 month ago Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...) Advicenne lève 2,6 millions d’euros grâce à une augmentation de capital, étend sa visibilité financière jusqu'à fin T3 2026 et renforce sa situation financière. Bpifrance détient désormais 23,95% du capital Augmentation De Capital Santé Bpifrance Advicenne Visibilité Financière
BRIEF published on 03/27/2025 at 19:17, 1 year 5 months ago Advicenne annonce une croissance solide et des projets futurs pour 2025 Amélioration Des Flux De Trésorerie Perspectives 2025 Résultats Financiers D'Advicenne Croissance Des Ventes De Sibnayal Progrès Réglementaires ADV7103
BRIEF published on 03/27/2025 at 19:17, 1 year 5 months ago Advicenne Reports Solid Growth and Future Plans for 2025 Cash Flow Improvement 2025 Outlook Advicenne Financial Results Sibnayal Sales Growth ADV7103 Regulatory Progress
PRESS RELEASE published on 03/27/2025 at 19:12, 1 year 5 months ago Inside Information / News release on accounts, results Advicenne reports successful commercial performance of Sibnayal® in Europe, with total product sales up 9.4% to €4.9m. Major strides in US development with NDA filing expected in Q3 2025 Financial Results Advicenne Commercial Performance Sibnayal US Development
PRESS RELEASE published on 03/27/2025 at 19:12, 1 year 5 months ago Informations privilégiées / Communiqué sur comptes, résultats Advicenne annonce ses résultats annuels 2024 avec un chiffre d'affaires en hausse de 9,4% grâce à Sibnayal® en Europe; avancées réglementaires majeures aux Etats-Unis Chiffre D'affaires Résultats Annuels États-Unis Advicenne Sibnayal
BRIEF published on 10/01/2024 at 07:05, 1 year 11 months ago Advicenne Advances in US with Positive FDA Reviews for ADV7103 FDA ADV7103 ATRd Advicenna Cystinuria
BRIEF published on 10/01/2024 at 07:05, 1 year 11 months ago Advicenne progresse aux États-Unis avec des avis positifs de la FDA sur ADV7103 FDA Advicenne ADV7103 ATRd Cystinurie
PRESS RELEASE published on 10/01/2024 at 07:00, 1 year 11 months ago Inside Information / Other news releases Advicenne achieves major milestones in the US with positive FDA opinions on ADV7103, accelerating partnership outlook for commercialization, preparing for clinical development in cystinuria, and seeking commercial partners Commercialization Advicenne ADV7103 Cystinuria FDA Opinions
PRESS RELEASE published on 10/01/2024 at 07:00, 1 year 11 months ago Informations privilégiées / Autres communiqués Advicenne franchit des étapes majeures aux Etats-Unis pour ADV7103 avec des avis favorables de la FDA, ouvrant des opportunités partenariales, simplifiant les démarches réglementaires et cliniques FDA Développement États-Unis Partenaires Advicenne
BRIEF published on 05/15/2024 at 09:07, 2 years 3 months ago Les actionnaires d'Advicenne approuvent les résolutions soutenues par le conseil d'administration lors de l'assemblée générale Assemblée Générale Euronext Croissance Paris Industrie Pharmaceutique Conseille Maladies Rénales Rares
Published on 09/12/2026 at 02:35, 11 hours 24 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 59 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 54 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 34 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 59 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 28 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 44 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 48 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 14 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 43 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
